Andrew Fish, executive director of AdvaMedDx, a division of the Advanced Medical Technology Association focused on diagnostics policy matters, praised the introduction of the MODDERN Cures Act in a statement.
The Modernizing Our Drug & Diagnostics Evaluation and Regulatory Network Cures Act aims to stimulate personalized medicine and renew therapies abandoned because they lack intellectual property protection.
"We applaud Rep. [Leonard] Lance for recognizing the importance of diagnostic tests and their role in critical aspects of health care, including development of personalized medicine," he said. "Current Medicare payment policies for diagnostics are severely flawed, and this bill would modernize Medicare reimbursement to better recognize the contribution of modern diagnostics to quality of patient care and better health outcomes. The 'MODDERN Cures Act' supports further discovery and innovation in diagnostics and more timely access for those in need by streamlining the inclusion of new diagnostics in Medicare, and ensuring appropriate reimbursement for diagnostic tests. We are hopeful this bill will gain wide support."
Related Articles on Supply Chain:
Profitability of Medical Device Companies Hurt by 2010 Healthcare Reform
GE Healthcare Announces $300M Investment in Low Radiation Dose Technology
Bristol and Pfizer Anticlotting Drug Gets FDA Priority Review
The Modernizing Our Drug & Diagnostics Evaluation and Regulatory Network Cures Act aims to stimulate personalized medicine and renew therapies abandoned because they lack intellectual property protection.
"We applaud Rep. [Leonard] Lance for recognizing the importance of diagnostic tests and their role in critical aspects of health care, including development of personalized medicine," he said. "Current Medicare payment policies for diagnostics are severely flawed, and this bill would modernize Medicare reimbursement to better recognize the contribution of modern diagnostics to quality of patient care and better health outcomes. The 'MODDERN Cures Act' supports further discovery and innovation in diagnostics and more timely access for those in need by streamlining the inclusion of new diagnostics in Medicare, and ensuring appropriate reimbursement for diagnostic tests. We are hopeful this bill will gain wide support."
Related Articles on Supply Chain:
Profitability of Medical Device Companies Hurt by 2010 Healthcare Reform
GE Healthcare Announces $300M Investment in Low Radiation Dose Technology
Bristol and Pfizer Anticlotting Drug Gets FDA Priority Review